𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness

✍ Scribed by Ahlame Saidi; Martin Hagedorn; Nathalie Allain; Chiara Verpelli; Carlo Sala; Lorenzo Bello; Andreas Bikfalvi; Sophie Javerzat

Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
627 KB
Volume
125
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Interleukin‐6 (IL6) and vascular endothelial growth factor (VEGFA) are abundantly produced by glioma cells and contribute to malignancy by promoting angiogenesis, cell proliferation and resistance to apoptosis. We compared the effect of inhibiting IL6 and VEGF on U87‐derived experimental glioma grown on the chick chorio‐allantoic membrane (CAM) or in the brain of xenografted mice. Tumor growth was monitored by biomicroscopy and immunohistology. In vitro, IL6 knockdown had no effect on proliferation but substantially enhanced invasion. In the CAM experimental glioma, IL6 or VEGF knockdown reduced growth and vascularization of the tumors with a comparable efficiency, but increased invasion of residual tumor cells. In contrast, combined IL6/VEGF knockdown not only showed enhanced reduction of tumor growth and angiogenesis but also significantly prevented invasion of residual tumor cells. In mice, combining IL6 knockdown and Avastin™ treatment completely abrogated tumor development and infiltration. Molecular response of tumor cells to single or combined treatment was studied by transcriptomic profiling. Many cell cycle promoting genes and chromatin components were silenced in the double knockdown. In addition, specific migratory signatures detected in tumors under single IL6 or VEGF knockdown were partially erased in combined IL6/VEGF knockdown tumors. Our results show that treatment with a combination of IL6 and VEGF inhibitors brings synergistic antitumoral benefit and reduces global activity of major pathways of cell survival, proliferation and invasiveness in remaining tumor cells that may be induced by using VEGF or IL6 inhibitors alone. © 2009 UICC

📜 SIMILAR VOLUMES

Somatostatin inhibits the production of
Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells
✍ Rolf Mentlein; Olaf Eichler; Frauke Forstreuter; Janka Held-Feindt 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 151 KB 👁 1 views

In various cell types, the neuro-and endocrine peptide somatostatin induces inhibitory and anti-secretory effects. Since somatostatin receptors, especially of the subtype sst2A, are constantly over-expressed in gliomas, we investigated the influence of somatostatin and the receptor subtype-selective

Tumor-targeting properties of antibody–v
Tumor-targeting properties of antibody–vascular endothelial growth factor fusion proteins
✍ Cornelia Halin; Uwe Niesner; Maria Elena Villani; Luciano Zardi; Dario Neri 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 293 KB

## Abstract A major problem of antibody‐based targeting of solid tumors is the poor penetration of antibodies into tumor tissue. Vasoactive immunoconjugates have been proposed as a means of increasing antibody uptake in tumors. In principle, VEGF (also known as vascular permeability factor) could s

Levels of vascular endothelial growth fa
Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis
✍ Nils Ole Schmidt; Manfred Westphal; Christian Hagel; Süleyman Ergün; Dimitrios S 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 288 KB 👁 2 views

Angiogenesis is a possible target in the treatment of human gliomas. To evaluate the role of 3 growth factors, vascular endothelial growth factor (VEGF), hepatocyte growth factor/scatter factor (HGF/SF) and basic fibroblast growth factor (bFGF), in the angiogenic cascade, we determined their levels